Roche Holding AG (RHHBY) announced today that the EMA's Committee for Medicinal Products for Human Use or CHMP recommended PiaSky as a monthly subcutaneous treatment for paroxysmal nocturnal haemoglobinuria or PNH for patients aged 12 and above, with a weight of 40 kg, who are new to or have received previous treatment with C5 inhibitors.
Roche said, if approved, PiaSky will become the first monthly subcutaneous treatment for PNH in the European Union, offering the option of self-administration as an alternative to current C5 inhibitors. PNH is a rare, life-threatening blood condition.
The CHMP's recommendation stems from the findings of the Phase III COMMODORE 2 study, which showed that PiaSky, given as SC injections every four weeks, controlled the disease and was well-tolerated.
The PiaSky as a monthly subcutaneous treatment is already sanctioned in the US, Japan, and China for individuals with PNH based on the results of the COMMODORE studies.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.